Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: A case report [6]

Leukemia

Volumn 20, Issue 4, 2006, Pages 734-736

  Anensen N ^a   Skavland, J ^a   Stapnes, C ^a   Ryningen, A ^a   Borresen Dale A L ^b   Gjertsen, B T ^a,c   Bruserud, Øystein ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD71 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P53; PROTEIN P63; PROTEIN P73; RETINOIC ACID; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; SYNAPTOPHYSIN; THEOPHYLLINE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; CASE REPORT; CELL PROLIFERATION; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; DRUG TARGETING; ENZYME INHIBITION; FAMILIAL CANCER; FEMALE; GENE INACTIVATION; HUMAN; HUMAN CELL; KARYOTYPE; LETTER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT WITHDRAWAL; WILD TYPE;

EID: 33646471989     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404117     Document Type: Letter

References (11)

1. Li FP, Fraumeni Jr JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362.
2. Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-2531.
4. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol 1992; 80: 178-183.
5. Pushkareva MY, Wannberg SL, Janoff AS, Mayhew E. Increased cellsurface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Immunol Immunother 2000; 48: 569-578.
6. Di Noto R, Lo Pardo C, Schiavone EM, Ferrara F, Manzo C, Vacca C et al. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma 1996; 21: 201-209.
7. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217-228.
8. Dimberg A, Nilsson K, Oberg F. Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood 2000; 96: 2870-2878.
9. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 2002; 196: 1373-1380.
10. Bruserud Ø, Stapnes C, Tronstad K, Ryningen A, Ånensen N, Gjertsen BT. Protein acetylation in normal and leukemic hematopoiesis: Histone deacetylases as possible therapeutic targets in acute myelogenous leukemia. Exp Opin Ther Targets 2006, (in press).
11. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65: 7386-7392.